全文获取类型
收费全文 | 18403篇 |
免费 | 861篇 |
国内免费 | 124篇 |
专业分类
耳鼻咽喉 | 106篇 |
儿科学 | 627篇 |
妇产科学 | 507篇 |
基础医学 | 2047篇 |
口腔科学 | 490篇 |
临床医学 | 1367篇 |
内科学 | 4838篇 |
皮肤病学 | 310篇 |
神经病学 | 1885篇 |
特种医学 | 900篇 |
外国民族医学 | 2篇 |
外科学 | 2487篇 |
综合类 | 51篇 |
一般理论 | 2篇 |
预防医学 | 817篇 |
眼科学 | 227篇 |
药学 | 997篇 |
中国医学 | 12篇 |
肿瘤学 | 1716篇 |
出版年
2023年 | 119篇 |
2022年 | 267篇 |
2021年 | 460篇 |
2020年 | 265篇 |
2019年 | 380篇 |
2018年 | 472篇 |
2017年 | 348篇 |
2016年 | 476篇 |
2015年 | 479篇 |
2014年 | 674篇 |
2013年 | 867篇 |
2012年 | 1318篇 |
2011年 | 1308篇 |
2010年 | 766篇 |
2009年 | 691篇 |
2008年 | 1273篇 |
2007年 | 1147篇 |
2006年 | 1209篇 |
2005年 | 1124篇 |
2004年 | 1099篇 |
2003年 | 986篇 |
2002年 | 911篇 |
2001年 | 200篇 |
2000年 | 155篇 |
1999年 | 216篇 |
1998年 | 196篇 |
1997年 | 166篇 |
1996年 | 138篇 |
1995年 | 137篇 |
1994年 | 118篇 |
1993年 | 119篇 |
1992年 | 129篇 |
1991年 | 105篇 |
1990年 | 100篇 |
1989年 | 83篇 |
1988年 | 80篇 |
1987年 | 74篇 |
1986年 | 77篇 |
1985年 | 55篇 |
1984年 | 81篇 |
1983年 | 49篇 |
1982年 | 58篇 |
1981年 | 42篇 |
1980年 | 44篇 |
1979年 | 32篇 |
1978年 | 33篇 |
1977年 | 25篇 |
1976年 | 21篇 |
1974年 | 21篇 |
1972年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
991.
Anat Norden-Zfoni Jayesh Desai Judith Manola Paul Beaudry Jeremy Force Robert Maki Judah Folkman Carlo Bello Charles Baum Sam E DePrimo David R Shalinsky Goerge D Demetri John V Heymach 《Clinical cancer research》2007,13(9):2643-2650
PURPOSE: There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those inhibiting the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway, and identify patients most likely to benefit from treatment. In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors. EXPERIMENTAL DESIGN: Patients (n=73) enrolled in a phase I/II trial received SU11248 daily for 14 or 28 days followed by 14 days without treatment per cycle. Clinical benefit was defined as progression-free survival of >6 months. We assessed plasma markers, including VEGF and soluble VEGFR-2 (sVEGFR-2), and two cellular populations bearing VEGF receptors: monocytes and, in a subset of patients, mature circulating endothelial cells (CEC). RESULTS: Compared to patients with progressive disease, patients with clinical benefit had significantly greater increases in CECs (0.52 versus -0.01 CEC/microL/d, P=0.03) and smaller decreases in monocyte levels (47% versus 60%, P=0.007) during cycle 1. VEGF increased by 2.2-fold and sVEGFR-2 decreased 25% during the first 2 weeks of treatment. Neither plasma marker correlated with clinical outcome although a modest inverse correlation was observed between sVEGFR-2 changes and plasma drug levels. Monocytes, VEGF, and sVEGFR-2 all rebounded towards baseline off treatment. CONCLUSIONS: Monocytes, VEGF, and sVEGFR-2 were consistently modulated by treatment, suggesting that they may serve as pharmacodynamic markers for SU11248. Changes in CECs and monocytes, but not the plasma markers, differed between the patients with clinical benefit and those with progressive disease. These end points merit further investigation in future trials to determine their utility as markers of SU11248 activity and clinical benefit in gastrointestinal stromal tumors and other tumor types. 相似文献
992.
Carlo Barone Michele Basso Giovanni Schinzari Carmelo Pozzo Nunziatina Trigila Ettore D'Argento Michela Quirino Antonio Astone Alessandra Cassano 《Gastric cancer》2007,10(2):104-111
Background In advanced gastric cancer few data are available on the efficacy or safety of new drug combination regimens after progression
following first-line chemotherapy.
Methods Patients with histologically confirmed advanced gastric cancer and Eastern Cooperative Oncology Group (ECOG) performance status
(PS) less than 2, progressing after first-line chemotherapy, were eligible. Patients were treated with docetaxel 75 mg/m2 on day 1 and oxaliplatin 80 mg/m2 on day 2, every 3 weeks, until progression or unacceptable toxicity.
Results Between May 2002 and April 2005, 38 patients were enrolled. Men accounted for 73.7% of the patients and the median age was
59 years. The primary tumor was not resected in 47.4% of the patients; the peritoneum was the most frequent metastatic site
(60.5%). The first-line treatment was cisplatin, epirubicin, and infusional 5-fluorouracil (ECF) in 81.5% of the patients
and cisplatin and infusional 5-fluorouracil (CF) in 15.7%. The median number of cycles was 4.3. The treatment was well tolerated,
with no toxic deaths. National Cancer Institute (NCI) grade III-IV neutropenia was frequent (26.3%), but no febrile neutropenia
was reported. Severe asthenia (15.7%) and severe nausea (15.7%) required dose reductions in 2 patients and treatment discontinuation
in another. The overall response rate was 10.5%, and 18 patients (47.3%) experienced disease stabilization (7 of them with
significant clinical benefit). Median time to progression was 4.0 months (range, 2–8 months) and median overall survival was
8.1 months (range, 3–26 months). Thirteen patients (34.2%) also received third-line chemotherapy, with an irinotecan-containing
regimen, and their median overall survival was higher than that of the other patients (16.3 vs 6.0 months)
Conclusion The combination of oxaliplatin and docetaxel shows only marginal activity as second-line treatment, but it has a good tolerability
profile. This suggests that there is room for optimizing the schedule as well as for planning sequential treatments in gastric
cancer. 相似文献
993.
Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models 总被引:1,自引:0,他引:1
Roberta Vitali Camillo Mancini Vincenzo Cesi Barbara Tanno Mariateresa Mancuso Gianluca Bossi Ying Zhang Robert V Martinez Bruno Calabretta Carlo Dominici Giuseppe Raschellà 《Clinical cancer research》2008,14(14):4622-4630
PURPOSE: We assessed the relevance of Slug (SNAI2) for apoptosis resistance and invasion potential of neuroblastoma cells in vitro and in vivo. EXPERIMENTAL DESIGN: We evaluated the effect of imatinib mesylate on invasion and analyzed the genes modulated by imatinib mesylate treatment in neuroblastoma cells. Slug expression, inhibited by imatinib mesylate treatment, was knocked down in neuroblastoma cells by RNA interference, and the effects on invasion and apoptosis were evaluated in vitro. A pseudometastatic model of neuroblastoma in severe combined immunodeficient mice was used to assess the effects of Slug silencing alone or in combination with imatinib mesylate treatment on metastasis development. RESULTS: Microarray analysis revealed that several genes, including Slug, were down-regulated by imatinib mesylate. Slug expression was detectable in 8 of 10 human neuroblastoma cell lines. Two Slug-expressing cell lines were infected with a vector encoding a microRNA to Slug mRNA. Infected cells with reduced levels of Slug were tested for the expression of apoptosis-related genes (p53, Bax, and Bcl-2) identified previously as Slug targets. Bcl-2 was down-regulated in Slug-interfered cells. Slug down-regulation increased sensitivity to apoptosis induced by imatinib mesylate, etoposide, or doxorubicin. Invasion of Slug-silenced cells was reduced in vitro. Animals injected with Slug-silenced cells had fewer tumors than controls and the inhibition of tumor growth was even higher in animals treated with imatinib mesylate. CONCLUSIONS: Slug down-regulation facilitates apoptosis induced by proapoptotic drugs in neuroblastoma cells and decreases their invasion capability in vitro and in vivo. Slug inhibition, possibly combined with imatinib mesylate, may represent a novel strategy for treatment of metastatic neuroblastoma. 相似文献
994.
Carlo PIRRI Paul KATRIS James TROTTER Evan BAYLISS Robert BENNETT Peter DRUMMOND 《Asia-Pacific Journal of Clinical Oncology》2008,4(3):161-169
Aim: Despite the paucity of controlled trials and possible interference with conventional treatments, complementary and alternative therapy (CAT) use is becoming increasingly popular and many patients do not discuss it with their physicians. Consequently, we examined the incidence and type of CAT use, perceived benefits of use, and the relationship between demographic, clinical or psychological factors and use in Western Australian patients. Methods: Two hundred newly diagnosed cancer patients beginning conventional multi‐modal treatment participated. Health‐related quality of life (HQOL), psychological adjustment and CAT use were assessed longitudinally at pretreatment, in treatment (at 8 weeks) and post‐treatment. Results: Overall, 30% of patients reported CAT use in the course of treatment. CAT users were predominantly younger (P = 0.004), tertiary educated (P = 0.016), possessed comorbid conditions (P = 0.023), and underwent lengthy treatment (P = 0.004). Patients who underwent lengthy treatment (>6 months) were three times more likely to use CAT than those who did not. Overall, 64% of CAT users perceived benefit from their use, primarily citing enhanced physical and emotional well‐being. CAT users, however, did not score significantly better than non‐users on any measure of HQOL, physical health or psychological function. CAT users generally reported greater psychosocial distress than non‐users across treatment, especially at pretreatment (baseline). However, with ongoing/new CAT use they significantly reduced their distress levels to that of non‐users by 8 weeks in treatment (P = 0.042). Conclusion: Complementary and alternative therapies enhanced cancer patients' psychological well‐being during the early stages of conventional treatment only. Use of CAT by cancer patients may be a clinical marker for psychosocial distress, and should trigger clinicians to inquire about physical symptoms, and concomitant anxiety and depression. 相似文献
995.
Is it possible to run a successful ovulation induction program based solely on ultrasound monitoring? The importance of endometrial measurements 总被引:2,自引:0,他引:2
OBJECTIVE: To attempt the monitoring of ovulation induction solely with ultrasound (US). DESIGN: Using serial US measurements to monitor ovulation induction using human menopausal gonadotropin and human chorionic gonadotropin (hCG), in comparison with estradiol (E2) concentrations that became available at the end of each cycle. SETTING: Specialist Reproductive Endocrine Unit. PATIENTS, PARTICIPANTS: Twenty hypogonadotropic and 29 ultrasonically diagnosed polycystic ovary patients. MAIN OUTCOME MEASURE: Follicular growth, uterine measurements, endometrial thickness, and serum E2 concentrations. RESULTS: Follicular growth, uterine measurements, and endometrial thickness correlated strongly with E2 concentrations (P less than 0.0001). The endometrium on the day of hCG administration was significantly thicker (P less than 0.01) in the conception (n = 27) compared with the nonconception cycles (n = 87), whereas no significant difference were observed in serum E2 concentrations. No pregnancy was observed when hCG had been administered when the endometrial thickness was less than or equal to 7 mm. Midluteal endometrial thickness of greater than or equal to 11 mm was found to be a good prognostic factor for detecting early pregnancy (P less than 0.008). CONCLUSIONS: Serial US examinations used alone have proven to be safe and highly efficient. It also has a unique ability to detect pregnancy in the midluteal phase. 相似文献
996.
Carlo La Vecchia Eva Negri Silvia Franceschi Barbara D’Avanzo Peter Boyle J. Larsson J. Permert G. Del Favero D. Basso P. Fogar M. P. Panozzo T. Meggiato C Ferrara F. D’Angeli L. Brigato M. Plebani Osamu Ishikawa Shoji Nakamori Hiroaki Ohigashi Singi Imaoka Åke AndrénSandberg Joe Ariyama Johan Permert Jörgen Larsson Parviz M. Pour Johan Permert Masashito Mogaki Katherine Kazakoff Lucio Gullo Raffaele Pezzilli Thomas E. Adrian Johan Permert Jörgen Larsson Gunilla T. Westermark 《Journal of gastrointestinal cancer》1994,16(1):81-98
997.
Christian Wittekmd Paul Hermanek Yoshifumi Kawarada Kentaro Yamagiwa Shuji Isaji Ryuji Mizumoto Di Carlo Valerio Zerbi Alessandro Balzano Gianpaolo Tsunoda Tsukasa Eto Toshifumi Tsuchiya Ryoichi Ishikawa Osamu Ohigashi Hiroaki Nakamori Shoji Imaoka Shingi H. G. Beger M. H. Schoenberg D. Birk Eugene P. DiMagno Tomioka Tsutomu Kanematsu Takashi Ariyama Joe Yamamoto Masahiro Ohashi Osamu Hidehumi Ishida Takashi Kamigaki Hirohiko Onoyama Yoichi Saitoh 《Journal of gastrointestinal cancer》1994,16(1):99-120
998.
999.
Preterm infants may demonstrate impaired ventilation during oral feeding with resultant hypoxemia and hypercarbia. This study was designed to determine whether infants activate a representative upper airway muscle, the ala nasi, in response to these ventilatory changes. Ten preterm infants (postconceptional age at study 35 +/- 4 wk, weight 2.2 +/- 0.1 kg) were studied during a control period, continuous feeding, subsequent intermittent feeding, and a period of nonnutritive sucking. Nasal airflow was measured with a pneumotachometer to quantify minute ventilation. The alae nasi electromyogram (EMGAN) was recorded with surface electrodes, and sucking pressure was detected by a catheter in the feeding nipple. End-tidal CO2 and O2 saturation were also recorded during each period. The percentage of breaths associated with EMGAN activity increased from 41 +/- 13% during the control period to 95 +/- 5% and 93 +/- 7% during continuous and intermittent sucking, respectively (p < 0.05). Eighty-seven +/- 5% of EMGAN activity occurred during inspiration. During continuous and intermittent sucking, the amplitude of EMGAN activity also increased (6.8 +/- 5.2 and 6.7 +/- 4.0 arbitrary units/breath, respectively) compared with the control period (2.4 +/- 2.8 units/breath, p < 0.05). In association with the increase in EMGAN activity, O2 saturation fell from 98 +/- 1% in the control period to 95 +/- 1% during both continuous and intermittent feeding (p < 0.05), and minute ventilation fell from 274 +/- 80 mL/min/kg during the control period to 190 +/- 81 and 208 +/- 57 mL/min/kg during continuous and intermittent feeding, respectively (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
1000.
Vittorio Silingardi Massimo Federico Luigi Cavanna Paolo Avanzini Paolo G. Gobbi Marco Lombardo Mario Carotenuto Antonio Frassoldati Carla Pieresca Daniele Vallisa Francesco Merli Edoardo Ascari Carlo Mauri 《Leukemia & lymphoma》1995,17(3):313-320
A randomized trial was designed in order to compare the efficacy and feasibility of ProMECE-CytaBOM (P-C) and MACOP-B (M-B) in patients with advanced, aggressive non Hodgkin's lymphoma (NHL). P-C and M-B were chosen due to their association with a very high complete remission rate when compared to other published protocols. The study was conducted on 210 patients with intermediate or high-grade NHL in stage I bulky, or stages II-IV, randomized to receive either 6 courses of P-C delivered every 28 days (106 patients), or 12 weeks of M-B chemotherapy (104 patients). In both regimens doxorubicin was replaced by a 20% higher dose of epidoxorubicin (i.e. 30 mg/m2 of the analog). At the end of induction therapy patients could receive additional radiotherapy to residual masses or to sites of previous bulky disease. The two groups of patients were compared for response rates, number and severity of therapy related side effects, overall survival, disease-free survival, and time to treatment failure.
Sixty-five patients (62%) treated with P-C and 69 patients (67%) treated with M-B achieved a complete remission, with no significant differences between the two treatment arms (P = 0.13). The overall objective response rate (complete + partial remission) was 74% for patients treated with P-C, and 81% for patients treated with M-B, respectively. The 4-year relapse-free survival rate was 59% for P-C and 69% for M-B, respectively (P = 0.11). We observed an eventual total of 120 treatment failures, 64 (61%) in the group treated with P-C and 56 (54%) among those treated with M-B (P = 0.29). Patients alive without disease at four years were estimated to be 42% in the P-C arm and 49% in the M-B arm (P = 0.27). The estimated 4-year overall survival was 54% for P-C and 61 % for M-B, and the differences were also not significant (P = 0.29). Patients treated with M-B experienced more and more severe side effects, including mucositis, infections, neurologic, pulmonary and cardiac abnormalities. Patients treated with P-C had a 1.3 g mean decrease of hemoglobin over the induction therapy, while patients treated with M-B experienced a 2.2 g mean decrease (P = 0.01).
In conclusion, both P-C and M-B resulted in effective treatment for patients with aggressive NHL, and provided similar activity. However P-C was more manageable in an outpatient setting and produced less acute toxic effects. 相似文献
Sixty-five patients (62%) treated with P-C and 69 patients (67%) treated with M-B achieved a complete remission, with no significant differences between the two treatment arms (P = 0.13). The overall objective response rate (complete + partial remission) was 74% for patients treated with P-C, and 81% for patients treated with M-B, respectively. The 4-year relapse-free survival rate was 59% for P-C and 69% for M-B, respectively (P = 0.11). We observed an eventual total of 120 treatment failures, 64 (61%) in the group treated with P-C and 56 (54%) among those treated with M-B (P = 0.29). Patients alive without disease at four years were estimated to be 42% in the P-C arm and 49% in the M-B arm (P = 0.27). The estimated 4-year overall survival was 54% for P-C and 61 % for M-B, and the differences were also not significant (P = 0.29). Patients treated with M-B experienced more and more severe side effects, including mucositis, infections, neurologic, pulmonary and cardiac abnormalities. Patients treated with P-C had a 1.3 g mean decrease of hemoglobin over the induction therapy, while patients treated with M-B experienced a 2.2 g mean decrease (P = 0.01).
In conclusion, both P-C and M-B resulted in effective treatment for patients with aggressive NHL, and provided similar activity. However P-C was more manageable in an outpatient setting and produced less acute toxic effects. 相似文献